- Messages
- 171
- Location
- London
Teleconference October 23rd 12PM EST by Edison Pharmaceuticals regarding progress of their investigational compound EPI-743 for mitochondrial diseases.
http://www.umdf.org/site/c.8qKOJ0MvF7LUG/b.8839795/k.7913/UMDF_MitoAction_Call_102313.htm
More about the company and their approach to this field which is designated 'orphan' disease status:
http://edisonpharma.com/About.aspx
This seems rather interesting because it could prove useful to a range of mitochondrial disorders..
http://www.umdf.org/site/c.8qKOJ0MvF7LUG/b.8839795/k.7913/UMDF_MitoAction_Call_102313.htm
More about the company and their approach to this field which is designated 'orphan' disease status:
http://edisonpharma.com/About.aspx
This seems rather interesting because it could prove useful to a range of mitochondrial disorders..